Get the Stockscreener App
5.99
7.16%
0.40
After Hours:
5.81
-0.18
-3.01%
Achieve Life Sciences Inc stock is traded at $5.99, with a volume of 2.83M.
It is up +7.16% in the last 24 hours and up +71.63% over the past month.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
See More
Previous Close:
$5.59
Open:
$5.35
24h Volume:
2.83M
Relative Volume:
2.72
Market Cap:
$614.93M
Revenue:
-
Net Income/Loss:
$-54.65M
P/E Ratio:
-4.6262
EPS:
-1.2948
Net Cash Flow:
$-49.47M
1W Performance:
+31.36%
1M Performance:
+71.63%
6M Performance:
+26.91%
1Y Performance:
+141.53%
1-Day Range:
$5.35
$6.15
1-Week Range:
$4.4085
$6.15
52-Week Range:
$2.00
$6.15
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Name
Achieve Life Sciences Inc
Sector
Industry
Phone
425-686-1500
Address
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
5.99 | 573.86M | 0 | -54.65M | -49.47M | -1.2948 |
VRTX
Vertex Pharmaceuticals Inc
|
448.29 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
723.41 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.81 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.03 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
315.07 | 32.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Nov-25-25 | Initiated | Citizens JMP | Mkt Outperform |
| Aug-21-25 | Initiated | H.C. Wainwright | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Sep-27-24 | Initiated | Raymond James | Strong Buy |
| May-10-23 | Reiterated | Maxim Group | Buy |
| Jun-23-21 | Initiated | Oppenheimer | Outperform |
View All
Achieve Life Sciences Inc Stock (ACHV) Latest News
Achieve Life Sciences (ACHV) registers 99.04M shares for resale by investors - Stock Titan
Achieve Life Sciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Achieve Life Sciences (ACHV) Secures $180M Financing for Cytisin - GuruFocus
Earnings call transcript: Achieve Life Sciences Q1 2026 beats EPS expectations - Investing.com
Achieve Life Sciences Q1 2026: Loss Narrows 38.7% to -$0.19/Share - AlphaStreet
Achieve Life Sciences Q1 Earnings Call Highlights - MarketBeat
ACHV: Achieve Aims for FDA Approval of Cytisinicline as New Smok - GuruFocus
How Should Investors Value Achieve Life Sciences (ACHV) After Q1 - GuruFocus
Achieve Life Sciences Releases Q1 2026 Financial Results - AlphaStreet
Achieve Life Sciences Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Achieve Life Sciences Closes $354M Financing, Advances Cytisinicline for Smoking & Vaping Cessation with FDA Review in 2026 - Minichart
Achieve Life Sciences Q1 loss narrows more than expected - TradingView
Q1 2026 Achieve Life Sciences Inc Earnings Call Transcript - GuruFocus
ACHV Stock Surges After Achieve Life Sciences Reports Market-Beating Q1 2026 Earnings - ChartMill
Achieve Life Sciences Adds Director Amid Board Transitions - TipRanks
Achieve Life Sciences adds three executives to leadership team - Investing.com
ACHIEVE LIFE SCIENCES, INC. 1Q 2026: Net loss $(10.2M), EPS $(0.19) — 10-Q Summary - TradingView
Achieve Life Sciences adds three executives to leadership team By Investing.com - Investing.com Canada
Achieve Life Sciences (NASDAQ: ACHV) posts Q1 loss, funds cytisinicline with $180M raise - Stock Titan
Achieve Life Sciences, Inc. unveils first quarter 2026 earnings and leadership update - Traders Union
Achieve Life Sciences (Nasdaq: ACHV) boosts cash with $354M private placement - Stock Titan
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma - ChartMill
Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates - ChartMill
Achieve Life Sciences Q1 2026 earnings preview - MSN
Citizens Initiates Coverage of Achieve Life Sciences (ACHV) with Market Outperform Recommendation - MSN
Wall Street Zen Upgrades Achieve Life Sciences (NASDAQ:ACHV) to Sell - MarketBeat
Achieve Life Sciences Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
ACHV Technical Analysis | Trend, Signals & Chart Patterns | ACHIEVE LIFE SCIENCES INC (NASDAQ:ACHV) - ChartMill
Number of shareholders of Achieve Life Sciences, Inc. – LS:A2QAR3 - TradingView
Franklin (NYSE: ACHV) reports 6.37M-share position, includes warrants - Stock Titan
Achieve Life Sciences (ACHV) to Release Quarterly Earnings on Tuesday - MarketBeat
Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026 - The Manila Times
Achieve Life will post quarterly results before a May 12 webcast - Stock Titan
Achieve Life Sciences : Corporate Presentation April 2026 (ACHV Corporate Deck April) - marketscreener.com
MSN Money - MSN
Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Canaccord Genuity initiates coverage of Achieve Life Sciences (ACHV) with buy recommendation - MSN
Achieve Life Sciences : Amendment to Annual Report (Form 10-K/A) - marketscreener.com
Board, pay and ownership details at Achieve Life Sciences (NASDAQ: ACHV) - Stock Titan
Goodwin Advises Marshall Wace On Co-Leading Achieve Life Sciences’ $354 Million Private Placement - Mondaq
venBio Global Strategic Fund V Secures Board Seat at Achieve Life Sciences with 9.99% Stake - TradingView
venBio funds take 9.99% Achieve Life stake, add board seat (ACHV) - Stock Titan
Achieve Life Sciences (ACHV) director Royston Aaron reports zero share ownership - Stock Titan
Achieve Life Sciences stock falls after pricing capital raise of $45M via securities offering - MSN
Achieve Life Sciences announces private placement of up to $354M - MSN
Achieve Life Sciences announces proposed public offering; shares down nearly 13% - MSN
Paradigm discloses 9.2% stake in Achieve Life (NASDAQ: ACHV) - Stock Titan
TPG takes 12.6% Achieve Life Sciences (ACHV) stake via $25M structured deal - Stock Titan
TPG-affiliated holders disclose Achieve Life Sciences (NASDAQ: ACHV) shares and warrants position - Stock Titan
Achieve Life Sciences (ACHV) director files Form 3 reporting zero share ownership - Stock Titan
Frazier Life Sciences (ACHV) holds 6.5% stake; warrants disclosed - Stock Titan
Achieve Life Sciences Inc Stock (ACHV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):